153 related articles for article (PubMed ID: 21514416)
21. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
22. The prognostic significance of p53, Bax, Bcl-2 and cyclin E protein overexpression in colon cancer - an immunohistochemical study using the tissue microarray technique.
Melincovici CS; Mihu CM; Mărginean M; Boşca AB; Coneac A; Moldovan I; Crişan M
Rom J Morphol Embryol; 2016; 57(1):81-9. PubMed ID: 27151692
[TBL] [Abstract][Full Text] [Related]
23. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.
Nardinocchi L; Puca R; Sacchi A; Rechavi G; Givol D; D'Orazi G
PLoS One; 2009 Aug; 4(8):e6819. PubMed ID: 19714248
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of miR-215 in colon cancer.
Karaayvaz M; Pal T; Song B; Zhang C; Georgakopoulos P; Mehmood S; Burke S; Shroyer K; Ju J
Clin Colorectal Cancer; 2011 Dec; 10(4):340-7. PubMed ID: 21752725
[TBL] [Abstract][Full Text] [Related]
25. HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage.
Iacovelli S; Ciuffini L; Lazzari C; Bracaglia G; Rinaldo C; Prodosmo A; Bartolazzi A; Sacchi A; Soddu S
Cell Prolif; 2009 Jun; 42(3):373-84. PubMed ID: 19438900
[TBL] [Abstract][Full Text] [Related]
26. Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2.
Gresko E; Roscic A; Ritterhoff S; Vichalkovski A; del Sal G; Schmitz ML
EMBO J; 2006 May; 25(9):1883-94. PubMed ID: 16601678
[TBL] [Abstract][Full Text] [Related]
27. HIPK2 expression in progression of cutaneous epithelial neoplasm.
Kwon MJ; Min SK; Seo J; Kim DH; Sung CO; Lim MS; Cho J; Park HR
Int J Dermatol; 2015 Mar; 54(3):347-54. PubMed ID: 25711204
[TBL] [Abstract][Full Text] [Related]
28. Zyxin is a critical regulator of the apoptotic HIPK2-p53 signaling axis.
Crone J; Glas C; Schultheiss K; Moehlenbrink J; Krieghoff-Henning E; Hofmann TG
Cancer Res; 2011 Mar; 71(6):2350-9. PubMed ID: 21248071
[TBL] [Abstract][Full Text] [Related]
29. HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations.
Di Stefano V; Mattiussi M; Sacchi A; D'Orazi G
FEBS Lett; 2005 Oct; 579(25):5473-80. PubMed ID: 16212962
[TBL] [Abstract][Full Text] [Related]
30. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
Puca R; Nardinocchi L; Givol D; D'Orazi G
Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
[TBL] [Abstract][Full Text] [Related]
31. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
D'Orazi G; Sciulli MG; Di Stefano V; Riccioni S; Frattini M; Falcioni R; Bertario L; Sacchi A; Patrignani P
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):735-41. PubMed ID: 16467083
[TBL] [Abstract][Full Text] [Related]
32. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity.
Tomasini R; Samir AA; Carrier A; Isnardon D; Cecchinelli B; Soddu S; Malissen B; Dagorn JC; Iovanna JL; Dusetti NJ
J Biol Chem; 2003 Sep; 278(39):37722-9. PubMed ID: 12851404
[TBL] [Abstract][Full Text] [Related]
33. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
Bhonde MR; Hanski ML; Budczies J; Cao M; Gillissen B; Moorthy D; Simonetta F; Scherübl H; Truss M; Hagemeier C; Mewes HW; Daniel PT; Zeitz M; Hanski C
J Biol Chem; 2006 Mar; 281(13):8675-85. PubMed ID: 16446370
[TBL] [Abstract][Full Text] [Related]
34. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis.
Di Stefano V; Rinaldo C; Sacchi A; Soddu S; D'Orazi G
Exp Cell Res; 2004 Feb; 293(2):311-20. PubMed ID: 14729469
[TBL] [Abstract][Full Text] [Related]
35. Expression of HIPK2 in cervical cancer: correlation with clinicopathology and prognosis.
Al-Beiti MA; Lu X
Aust N Z J Obstet Gynaecol; 2008 Jun; 48(3):329-36. PubMed ID: 18532967
[TBL] [Abstract][Full Text] [Related]
36. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation.
Rui Y; Xu Z; Lin S; Li Q; Rui H; Luo W; Zhou HM; Cheung PY; Wu Z; Ye Z; Li P; Han J; Lin SC
EMBO J; 2004 Nov; 23(23):4583-94. PubMed ID: 15526030
[TBL] [Abstract][Full Text] [Related]
37. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
38. Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy.
Garufi A; Ricci A; Trisciuoglio D; Iorio E; Carpinelli G; Pistritto G; Cirone M; D'Orazi G
Cell Death Dis; 2013 May; 4(5):e639. PubMed ID: 23703384
[TBL] [Abstract][Full Text] [Related]
39. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
[TBL] [Abstract][Full Text] [Related]
40. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
